Trial Profile
Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2023
Price :
$35
*
At a glance
- Drugs VRC-CHKVLP059-00-VP (Primary)
- Indications Chikungunya virus infections
- Focus Adverse reactions
- 08 Sep 2023 Results of a post hoc analysis comparing safety and immunogenicity of CHIKV VLP vaccine in seropositive (n = 39) versus seronegative (n = 155) vaccine recipients for 72 weeks post-vaccination published in the Vaccine
- 26 May 2021 Results published in the Media Release
- 14 Apr 2020 Results published in the JAMA: the Journal of the American Medical Association.